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Abstract 
Lymphoma remains the most frequent neoplastic 
cause of death among HIV-infected individuals. 
Lymphomas in patients infected with HIV are 
heterogeneous, not only pathologically but also in 
terms of pathogenetic pathways and cellular 
derivation. This CARD summarizes the association 
of the different types of HIV-associated lymphomas 
with known genetic lesions and/or oncogenic 
viruses. In the setting of HIV infection different, but 
not mutually exclusive, pathogenic pathways might 
occur. For a distinct pathway of AIDS-related 
lymphomagenesis there can be multiple associated 
genetic lesions in the tumor. Several of the HIV-
associated lymphomas are also related to EBV 
and/or KSHV (HHV-8) infection. 
Keywords: AIDS-related lymphoma; HIV-
associated lymphoma; HIV; lymphoma, gamma 
herpesviruses 
Identity 
Other names: AIDS-related lymphomas, HIV-
related lymphomas;, Lymphomas associated with 
HIV infection 
Clinics and pathology 
Disease 
The most common lymphomas arising in HIV-
infected individuals include Burkitt lymphoma (BL) 
and diffuse large B-cell lymphoma (DLBCL).  
Classical Hodgkin lymphoma (cHL) is also 
common. Other lymphomas include primary 
effusion lymphoma (PEL) and its solid variants, 
lymphoma associated with Kaposi sarcoma 
herpesvirus (KSHV)-related multicentric Castleman 
Disease (MCD), and plasmablastic lymphoma (PBL) 
(Table 1) (IARC 2012; Dolcetti et al., 2016;). The 
latter three types of lymphomas rarely occur in the 
general population. 
Epidemiology 
Lymphoma is still the most frequent neoplastic cause 
of death among HIV-infected individuals (Grulich et 
al., 2015). Young and middle-aged people afflicted 
with HIV infection are most often affected.  
The age of lymphoma occurrence is dependent on 
the patient's age of HIV infection. Although the 
incidence of HIV-associated non-Hodgkin 
lymphomas has declined after the introduction of 
combination antiretroviral therapy (cART), these 
lymphomas remain the main type of cancer to be 
detected in HIV-infected people.  
Curiously, the incidence of cHL has increased since 
the Highly Active Antiretroviral (HAART) era 
whereas the incidence of other HIV-associated 
lymphomas remains stable. This high incidence of 
lymphomas, despite the immunoreconstitution 
promoted by cART, strongly suggests that factors 
other than HIV-related immunosuppression are 
probably still acting as lymphomagenic factors in the 
HIV setting (Pantanowitz et al., 2015; Dolcetti et al., 
2016;). 
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Burkitt lymphoma- mostly plasmacytoid 
Primary central nervous system lymphoma  
Diffuse large B-cell lymphoma, including primary central nervous system lymphoma (immunoblastic, 
plasmacytoid and centroblastic) 
Plasmablastic lymphoma  
Primary effusion lymphoma (PEL) and its solid variant (Classic PEL - in the absence of tumor masses; Solid 
PEL with or without serous effusion) 
Multicentric Castleman Disease (MCD)-associated large cell lymphoma  
Hodgkin lymphoma  
Other histotypes (rare) 
  Marginal zone lymphoma  
  
Unclassifiable lymphomas with features intermediate between Burkitt lymphoma and diffuse large B-cell 
lymphoma 
  Polymorphic B-cell lymphoma (PTLD-like)  
 
Table 1. Categories of HIV-associated lymphomas 
 
Clinics 
Sex. There is an apparently higher risk of HIV-
associated lymphomas in men than women. 
Site. Lymphomas that develop in HIV-infected 
patients are predominantly aggressive B-cell 
malignancies.  
These lymphomas display a marked propensity to 
involve extra-nodal anatomic sites such as the 
central nervous system, gastrointestinal tract, liver, 
bone marrow, and perinodal soft tissue. At diagnosis, 
most patients with HIV-associated HL present with 




Most HIV-associated lymphomas present with extra-
nodal tumour masses, lymphadenopathy with 
necrosis, and/or effusion. 
Microscopy 
Burkitt lymphoma (BL). HIV-associated BL 
includes cases that exhibit classic BL features, as 
well as cases that show plasmacytoid differentiation 
(Gloghini et al., 2013). 
Diffuse large B-cell lymphoma (DLBCL). DLBCL 
can be morphologically heterogeneous. The different 
morphological variants of DLBCL include the 
centroblastic variant, immunoblastic variant (which 
requires there to be at least 90% of  
immunoblasts with plasmacytoid features), and the 
anaplastic variant (Carbone et al., 2001; Gloghini et 
al., 2013).  
Primary DLBCL of the central nervous system 
(PCNSL) associated with HIV infection usually 
belongs to the immunoblastic type. 
Primary effusion lymphoma (PEL). Lymphoma cells 
range from large tumor cells showing anaplastic 
morphology to cells with immunoblastic or 
plasmablastic morphology.  
These lymphomas frequently display a certain 
degree of plasma cell differentiation (Carbone et al., 
2001; Cesarman et al., 1995). 
Plasmablastic lymphoma (PBL).  
These lymphomas can be subdivided into two 
morphologic subgroups: 1) lymphomas comprised 
of a monomorphic population of plasmablasts with 
no/minimal plasmacytic differentiation, and 2) 
lymphomas with plasmacytic differentiation, 
composed of plasmablasts and cells showing plasma 
cell differentiation (Delecluse et al., 1997; Stein et 
al., 2008). 
Classical Hodgkin lymphoma (cHL). cHL is 
currently the most common type of non-AIDS-
defining cancer.  
Common encountered histological subtypes in HIV-
positive patients include mixed cellularity and 
lymphocyte depleted cHL (Carbone et al., 2014; 
Uldrick and Little, 2015). 
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Figure 2. HIV-associated pericardial primary effusion lymphoma (cell block preparation, H&E stain, 40x magnification). 
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BL: CD45+, CD20+, CD10+, BCL6+, BCL2-, 
MYC+, Ki67+ 100% 
DLBCL (CB): CD45+, CD20+, BCL6+, 
MUM1/IRF4-, CD138- 
DLBCL (IB): CD45+, CD20-/+, BCL6-, 
MUM1/IRF4+, CD138- 
DLBCL (IB with plasmacytoid features): CD45+/-, 
CD20-/+, BCL6-, MUM1/IRF4+, CD138+ 
PEL: CD45+, CD20-, T/NK markers+/-, CD30+, 
CD138+, EMA+/-, LNA-1+ 
PBL. CD45+/-, CD20+/-, CD79a+/-, PAX5-, 
CD138+, EMA+/-, CD31-/+, LNA-1- 
cHL (Reed Sternberg cells): CD45-, CD20-/+, 
PAX5+, CD30+, CD15+/-, OCT-2+, BOB.1-, 
LMP1+ 
Treatment 
The combination of cART and chemotherapy 
treatment has resulted in a remarkable prolongation 
of survival among HIV-infected patients with 
lymphoma. Safety and efficacy of combined 
treatment including rituximab plus chemotherapy 
(R-CT) has been documented (Dunleavy and 
Wilson, 2012; Carbone et al., 2014). HIV-associated 
Hodgkin lymphoma shows unusually aggressive 
clinical behaviour, which mandates the use of 
specific therapeutic strategies. The combination of 
cART with better supportive therapy has made 
standard ABVD (doxorubicin, bleomycin, 
vinblastine, dacarbazine) and intensive 
chemotherapy regimens feasible in patients with 
HIV-associated Hodgkin lymphoma (Carbone et al., 
2014; Uldrick and Little, 2015). 
Prognosis 
The outcome of HIV-associated lymphomas 
including Non-Hodgkin and Hodgkin lymphomas 
has dramatically improved since the introduction of 
cART with intensive chemotherapy regimens 
(Carbone et al., 2014;Uldrick and Little, 2015). 
Immunodeficiency states usually increase 
susceptibility to cancer as a result of reduced 
immune surveillance and enhanced chances for 
viral-driven oncogenesis. The viral contribution to 
the development of HIV-associated malignancies 
has been extensively studied (IARC 2012); but only 
two oncogenic viruses -i.e., Epstein Barr virus 
(EBV) and Kaposi sarcoma-associated herpesvirus 
(KSHV)/Human Herpresvirus-8 (HHV8) - have 
been pathogenically associated with specific 
lymphomas occurring in the HIV setting (Carbone et 
al., 2009).  
Table 2 lists those lymphoid proliferations occurring 
in HIV-infected patients that are known to be 
associated with infection by EBV and/or KSHV.  
Importantly, these co-infected lymphomas are 
frequently associated with single or multiple genetic 
lesions, as shown in Table 2 (Carbone et al., 2001; 
Chadburn et al., 2013). The HIV virus itself is 
thought to contribute to lymphomagenesis through 
induction of chronic B-cell activation, due to HIV-
mediated immune dysfunction. In summary, the 
pathogenesis of HIV-associated lymphomas is the 
result of different factors including impaired 
immune surveillance, genetic alterations, viral 
infection and chronic B-cell activation. 
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Histotype  BL DLBCL-CB DLBCL-IB PBL PEL 
Viral Infection           
           EBV +/- -/+ + +/- +/- 
           KSHV - - - - + 
Genetic abnormalities            
           BCL2 - - 30% 20% - 
           BCL6 100% >75% - <10% - 
           TP53 50-60% Rare - - - 
           MYC 100% 0-50% - 40% - 
Table 2. Co-infected  lymphomas in people with HIV/AIDS S 
Abbreviations. BL, Burkitt lymphoma; CB, centroblastic; DLBCL,  diffuse large B-cell lymphoma; EBV, Epstein Barr virus; HIV, 
human  immunodeficiency virus; IB, immunoblastic; KSHV, Kaposi  sarcoma-associated herpesvirus; PEL, primary effusion 
lymphoma; PBL, plasmablastic lymphoma; +, positive in 100% of cases; -, negative in 100% of cases; -/+, positive in less  than 
50% of cases; +/-, positive in more than 50% of cases 
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